SecBot SecBot
PRESS-RELEASE ·Filed May 5, 2026

OCGN

Ocugen
BEARISH
Impact 7/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · Activist
Actionable Insight ▼ Bearish

The 6.75% coupon and 90% issue price indicate high credit risk. With $626M market cap and $115M debt, leverage increases significantly. Monitor for potential stock price pressure as conversion shares may be hedged or sold. The greenshoe option adds further overhang. Watch for any pipeline updates that could offset dilution concerns.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.49
T+0 close · May 5, 2026 · via day close
Latest settled
−15.44%
T+60 · $1.26
Vs SPY
−18.18%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 5 $1.49entry
  2. T+1 · 7mo ago −2.35%α −3.73% · $1.46
  3. T+5 · 6mo ago −0.67%α −2.66% · $1.48
  4. T+20 · 6mo ago −10.07%α −15.02% · $1.34
  5. T+60 · 4mo ago −15.44%α −18.18% · $1.26
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Ocugen priced $115M of 6.75% convertible senior notes due 2034 at a 90% discount to par, with net proceeds of ~$99.5M ($112.6M if greenshoe exercised). The offering is dilutive (conversion price ~$2.68, 45% premium to $1.85 close) and will repay $32.7M of Avenue Capital debt, with the rest for general corporate purposes. Given the company's $626M market cap, this is a material capital raise that increases leverage and dilution risk.

Key Financial Metrics

Deal Value
$115.0M

Key Facts

  • $115M aggregate principal of 6.75% convertible senior notes due 2034 priced at 90% of par
  • Initial purchaser has 13-day option for additional $15M of notes
  • Net proceeds ~$99.5M (~$112.6M if greenshoe exercised)
  • ~$32.7M of net proceeds to repay Avenue Capital loan; remainder for general corporate purposes
  • Conversion price ~$2.68 per share (45% premium to $1.85 close on May 4, 2026)
  • Initial conversion rate: 372.7866 shares per $1,000 principal
  • Notes mature May 15, 2034; interest 6.75% semi-annual; callable after May 15, 2029 under stock price conditions
  • Holders can put notes at par on May 15, 2032 or upon fundamental change
  • Conversion may be settled in cash, stock, or combination at Ocugen's election; cash settlement until reserved share effective date
  • Offering to close May 7, 2026

Financial Impact

$115M principal at 90% price = $103.5M gross; net ~$99.5M; $32.7M debt repayment; remaining ~$66.8M for corporate purposes. Dilution: up to ~42.9M shares if fully converted (at $2.68 conversion price), representing ~6.9% of current 626M market cap at $1.85/share.

dilutiondebtcashinterest expense

Risk Factors

  • Dilution from conversion of notes (~42.9M shares at $2.68) could pressure stock price
  • High 6.75% interest cost adds ~$7.8M annual interest expense
  • 90% issue price implies weak demand and credit concerns
  • Cash settlement until reserved share effective date may limit immediate dilution but creates future overhang
  • General corporate purposes use of proceeds lacks specific catalyst

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
92% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3287656

Track record

23 reports on OCGN

Performance horizon

2 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +20.49% at T+20 after the Jun 11, 2026 report. 3 of 5 went positive at some point.

Filters
  1. Nov 10, 20266d ago 8-K Neutral 4/10 Entry $0.9500 to $0.9604 Now $0.7730 −18.63% ▲ +1.09% −0.22% vs SPY
  2. Nov 10, 20266d ago Press Release Neutral 4/10 Entry $0.9500 to $0.9604 Now $0.7730 −18.63% ▲ +1.09% −0.22% vs SPY
  3. Nov 6, 202610d ago DEFA14A Neutral 2/10 Entry $0.9721 to $0.9500 Now $0.7730 −20.48% ▼ −2.27% −1.91% vs SPY
  4. Nov 6, 202610d ago DEFA14A Neutral 3/10 Entry $0.9721 to $0.9500 Now $0.7730 −20.48% ▼ −2.27% −1.91% vs SPY
  5. Nov 4, 202612d ago 8-K Neutral 4/10 No price data
  6. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $0.8745 to $0.8165 Now $0.7730 −11.61% ▼ −6.63% −2.22% vs SPY
  7. Oct 15, 20264w ago 8-K Neutral 5/10 Entry $0.8137 to $0.7803 Now $0.7730 −5.00% ▼ −4.10% −3.00% vs SPY
  8. Oct 14, 20264w ago 8-K Mixed 5/10 Entry $0.8137 to $0.7803 Now $0.7730 −5.00% ▼ −4.10% −3.00% vs SPY
  9. Oct 9, 20265w ago 144 Neutral 2/10 Entry $0.9472 to $0.8854 Now $0.7730 −18.39% ▼ −6.52% −6.51% vs SPY
  10. Sep 1, 202610w ago Press Release Bullish 7/10 Entry $1.33 to $1.32 Now $0.7730 −41.88% ▼ −0.75% −1.20% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 5, 2026